Last updated: May 4, 2026
What companies supply “RENO-60” (renoprotective/renal-support product) and what is verifiable from public sourcing?
Which suppliers can be confirmed for “RENO-60”?
No complete, verifiable supplier set can be produced because “RENO-60” is not a uniquely identifiable pharmaceutical product designation across jurisdictions from the information provided. “RENO-60” is used in markets as a brand-style label for different compositions, package formats, and strengths, and supplier lists are composition-specific (manufacturer of the drug substance, finished dosage manufacturer, and branded-marketer).
Because the request does not include:
- the active pharmaceutical ingredient (API) name(s),
- dosage form (tablet/capsule/sachet, etc.),
- strength confirmation beyond “60”,
- country/market (e.g., India vs. GCC vs. EU),
there is no auditable way to map “RENO-60” to a single product record and therefore no defensible supplier list.
What suppliers are typically involved for a labeled renal-support product?
A complete supplier map normally splits into these roles (and each role is tied to the exact product record for the same strength and salt form):
- API manufacturer (drug substance)
- Finished dosage manufacturer (tablet/capsule producer)
- Branded marketer / brand owner (the company marketing “RENO-60” in a given market)
- Packager and labeler (often the same as the branded marketer, sometimes separate)
Without the unique product record, any named suppliers would risk cross-linking different “RENO-60” variants.
Key Takeaways
- A reliable supplier list for “RENO-60” cannot be generated from the brand label alone because “RENO-60” is not uniquely identifiable across markets and compositions.
- Supplier identification must be tied to the exact API, salt form, dosage form, strength, and market-specific product record.
- Named suppliers would otherwise be speculative and not usable for R&D or investment diligence.
FAQs
1) Is “RENO-60” a single globally standardized pharmaceutical product name?
No. Brand-style labels like “RENO-60” are not globally standardized and can correspond to different APIs, strengths, and formulations across markets.
2) What supplier types should be listed for diligence?
API manufacturer, finished dosage manufacturer, branded marketer/brand owner, and packager/labeler.
3) Why can’t suppliers be listed directly from the label name?
Because the label name does not uniquely identify the drug substance, salt form, dosage form, or the regulatory product record in a specific market.
4) What evidence is usually required to name suppliers accurately?
Regulatory product details (label/leaflet), registration records, and manufacturing/distribution listings tied to the same strength and formulation.
5) Can I get supplier names without specifying API and market?
Not in a way that is verifiable and decision-grade for patent and sourcing work.
References
[1] (No cited sources available from the provided prompt.)
